Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

A Phenomenal Legacy for London 2012

Published: Wednesday, August 01, 2012
Last Updated: Wednesday, August 01, 2012
Bookmark and Share
The Phenome Centre will use the cutting edge facilities developed for London 2012 to help develop better and more targeted treatment for patients.

The London 2012 anti-doping facilities will be developed after the Olympic and Paralympic Games into a world-class resource that could help revolutionise healthcare. The MRC-NIHR Phenome Centre will use the cutting edge facilities developed for London 2012 to help develop better and more targeted treatment for patients.
The MRC-NIHR Phenome Centre, the first of its kind in the world, will enable researchers to explore the characteristics of disease in order to develop new drugs and treatments for patients.
A phenome describes a person’s chemistry – all the molecules in their blood, urine or tissues – that are the result of their genetics and their lifestyle. This mixture of molecules is changing all the time and is influenced by factors such as diet, environment and even stress levels. It is linked to how a person responds to disease or to treatments such as drugs.
Researchers at the Centre will investigate the phenome patterns of patients and volunteers by analysing samples – usually blood or urine – very rapidly and on an unprecedented scale. This will help them to discover new ‘biomarkers’ to explain why one individual or population may be more susceptible to a disease than another. This knowledge will aid scientists in finding new, safer and more targeted treatments. Phenome analysis has already been used to ‘tailor’ cancer treatment to suit individual patients by, for example, minimising the toxicity and maximising the efficiency of drug treatments for colon cancer.
The new Centre will be funded over five years by an investment of £5 million each from the Medical Research Council (MRC) and the Department of Health’s National Institute for Health Research (NIHR) and will build on and develop the state-of-the-art equipment and expertise of the London 2012 anti-doping facilities provided by GlaxoSmithKline (GSK) and operated by King’s College London.
The MRC-NIHR Phenome Centre will enable the UK to make its world-class phenotyping technology and expertise available to both researchers and the life sciences industry to accelerate the translation of medical discoveries into better healthcare. The new Centre will be led by a collaboration of academic partners, led by Imperial College London, and the suppliers of nuclear magnetic resonance and mass spectrometry equipment (Bruker and Waters Corporation).
Professor Sir John Savill, Chief Executive of the MRC, said:

“The UK has an extremely strong life sciences capability and world-class expertise in this area of research. The GSK drug-testing facility at Harlow has taken one of the major challenges associated with this type of research – achieving high-throughput alongside forensic quality control – to a new level, unprecedented anywhere in the world. Rather than losing this investment once the Games are over the collaboration – involving the MRC, NIHR, UK universities, the NHS and NIHR Biomedical Research Centres, and industry leaders in the field – will provide a unique resource that will ultimately result in benefits for patients. This is a phenomenal legacy from the Games.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Study Identifies New Way to Kill the Malaria Parasite
Scientists have discovered new ways in which the malaria parasite survives in the blood stream of its victims, a discovery that could pave the way to new treatments for the disease.
Tuesday, July 07, 2015
AstraZeneca, MRC Collaboration to Create New Centre for Early Drug Discovery
The Companies today announced the groundbreaking collaboration aimed at better understanding the mechanisms of human disease. The collaboration will see the creation of a joint research facility at AstraZeneca’s new R&D centre in Cambridge in the UK.
Monday, March 31, 2014
Scientists Edge Closer Towards First Pancreatitis Treatment
Scientists have provided proof of principle for a drug-based treatment of acute pancreatitis – a disease for which currently there is no treatment.
Friday, July 26, 2013
MRC Delivering on the Life Sciences Strategy, One Year On
The Medical Research Council has made significant progress in implementing the measures outlined in last year’s Strategy for UK Life Sciences, according to a progress update published by the Government.
Tuesday, December 11, 2012
MRC and AstraZeneca Scoop Prestigious SCRIP Award
The innovative collaboration between the Medical Research Council and AstraZeneca has won the ‘Best Partnership Alliance’ award at the annual SCRIP Awards.
Tuesday, December 04, 2012
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos